AIM ImmunoTech (AIM) announced that the Company’s Board of Directors has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIM:
- AIM ImmunoTech doses first subject in Phase 2 study of Ampligen, Imfinzi
- AIM ImmunoTech to not proceed with offering pursuant to registration statement
- AIM ImmunoTech announces follow-up clinical study of Ampligen with FluMist
- AIM ImmunoTech announces Safety Committee approval to proceed with Phase 2
- AIM ImmunoTech files to sell units, no amount given